OxSyBio
London
About OxSyBio
OxSyBio's vision is to ultimately produce tissues that can be used by patients in the clinic for precision medicine and organ repair or replacement. At OxSyBio, they are developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical research and clinical applications. Their technology is based on cutting-edge research conducted by Professor Hagan Bayley’s group in the Chemistry Department at the University of Oxford. A leader in the exploration of chemical and synthetic biology his expertise cover membrane protein structure and function, single molecule chemistry and 3D printing.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2018)
- Website: oxsybio.com
- Phone: 01133845825
Industries & Categories
3D Printing, 3D Technology, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/oxsybio-197823 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.